The global heart valve frame market is poised for significant growth over the coming years, driven by factors such as increasing prevalence of cardiovascular ...

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...